Literature DB >> 7620157

Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor.

H Lankhof1, Y P Wu, T Vink, M E Schiphorst, H G Zerwes, P G de Groot, J J Sixma.   

Abstract

To assess the relative importance of the glycoprotein (GP) Ib binding domain and the RGDS binding site in platelet adhesion to isolated von Willebrand factor (vWF) and to collagen preincubated with vWF, we deleted the A1 domain yielding delta A1-vWF and introduced an aspartate-to-glycine substitution in the RGDS sequence by site-directed mutagenesis (RGGS-vWF). Recombinant delta A1-vWF and RGGS-vWF, purified from transfected baby hamster kidney cells, were compared with recombinant wild-type vWF (WT-vWF) in platelet adhesion under static and flow conditions. Purified mutants were coated on glass or on a collagen type III surface and exposed to circulating blood in a perfusion system. Platelet adhesion under static condition, under flow conditions, and in vWF-dependent adhesion to collagen has an absolute requirement for GPIb-vWF interaction. The GPIIb/IIIa-vWF interaction is required for adhesion to coated vWF under flow conditions. Under static condition and vWF-dependent adhesion to collagen, platelet adhesion to RGGS-vWF is similar as to WT-vWF, but platelet spreading and aggregation are abolished.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620157

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Functional self-association of von Willebrand factor during platelet adhesion under flow.

Authors:  Brian Savage; Jan J Sixma; Zaverio M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-26       Impact factor: 11.205

2.  Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.

Authors:  T L Slobodianuk; C Kochelek; J Foeckler; S Kalloway; H Weiler; V H Flood
Journal:  J Thromb Haemost       Date:  2018-12-18       Impact factor: 5.824

Review 3.  Molecular genetics of type 2 von Willebrand disease.

Authors:  Edith Fressinaud; Claudine Mazurier; Dominique Meyer
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

4.  Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.

Authors:  Veronica H Flood; Joan Cox Gill; Patricia A Morateck; Pamela A Christopherson; Kenneth D Friedman; Sandra L Haberichter; Raymond G Hoffmann; Robert R Montgomery
Journal:  Blood       Date:  2010-12-10       Impact factor: 22.113

5.  A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF.

Authors:  Sara Zanardelli; Alain C K Chion; Evelyn Groot; Peter J Lenting; Thomas A J McKinnon; Mike A Laffan; Michelle Tseng; David A Lane
Journal:  Blood       Date:  2009-07-08       Impact factor: 22.113

Review 6.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

7.  Shear stress and platelet-induced tensile forces regulate ADAMTS13-localization within the platelet thrombus.

Authors:  Yasuaki Shida; Laura L Swystun; Christine Brown; Jeffrey Mewburn; Kate Nesbitt; Ozge Danisment; Jonathan Jacob Riches; Christine Hough; David Lillicrap
Journal:  Res Pract Thromb Haemost       Date:  2019-03-23

8.  Interaction of von Willebrand factor with blood cells in flow models: a systematic review.

Authors:  Ryanne A Arisz; Judith J de Vries; Saskia E M Schols; Jeroen C J Eikenboom; Moniek P M de Maat
Journal:  Blood Adv       Date:  2022-07-12

9.  On the versatility of von Willebrand factor.

Authors:  Antoine Rauch; Nikolett Wohner; Olivier D Christophe; Cécile V Denis; Sophie Susen; Peter J Lenting
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-07-10       Impact factor: 2.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.